Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 77, No. 6, 2010
Issue release date: January 2011
Section title: Original Paper
Pathobiology 2010;77:301–308
(DOI:10.1159/000321567)

Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Micromilieu of Classical Hodgkin Lymphoma

Tzankov A. · Matter M.S. · Dirnhofer S.
Department of Pathology, University of Basel, Basel, Switzerland
email Corresponding Author

Dr. A. Tzankov

Department of Pathology

University of Basel, Schoenbeinstrasse 40

CH–4031 Basel (Switzerland)

Tel. +41 61 328 68 80, Fax +41 61 265 31 94, E-Mail atzankov@uhbs.ch


References

  1. Tzankov A, Dirnhofer S: Pathobiology of classical Hodgkin lymphoma. Pathobiology 2006;73:107–125.
  2. Diehl V, Engert A, Re D: New strategies for the treatment of advanced-stage Hodgkin’s lymphoma. Hematol Oncol Clin North Am 2007;21:897–914.
  3. David KA, Mauro L, Evens AM: Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol 2007;8:352–374.
  4. Landgren O, Caporaso NE: New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin’s lymphoma. Hematol Oncol Clin North Am 2007;21:825–840.
  5. MacLennan KA, Bennett MH, Tu A, Hudson BV, Easterling MJ, Hudson GV, Jelliffe AM: Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. A study of 1659 patients. Cancer 1989;64:1686–1693.
  6. Lukes RJ, Butler JJ, Hicks EB: Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer 1966;19:317–344.
    External Resources
  7. Keller AR, Kaplan HS, Lukes RJ, Rappaport H: Correlation of histopathology with other prognostic indicators in Hodgkin’s disease. Cancer 1968;22:487–499.
  8. Hess JL, Bodis S, Pinkus G, Silver B, Mauch P: Histopathologic grading of nodular sclerosis Hodgkin’s disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994;74:708–714.
  9. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339:1506–1514.
  10. Josting A, Wolf J, Diehl V: Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000;12:403–411.
  11. Tzankov A, Krugmann J, Fend F, Fischhofer M, Greil R, Dirnhofer S: The prognostic value of CD20 expression in classical Hodgkin Lymphoma – a clinico-pathological study of 119 cases. Clin Cancer Res 2003;9:1381–1386.
  12. Krugmann J, Tzankov A, Gschwendtner A, Fischhofer M, Greil R, Fend F, Dirnhofer S: Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin’s lymphoma: a single-institution study. Mod Pathol 2003;16:566–573.
  13. Poppema S, Potters M, Emmens R, Visser L, Van den Berg A: Immune reactions in classical Hodgkin’s lymphoma. Semin Hematol 1999;36:253–259.
  14. Poppema S, Van den Berg A: Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10:345–350.
  15. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, Meijer CJ: Activated cytotoxic T cells as prognostic marker in Hodgkin’s disease. Blood 1997;89:1376–1382.
  16. Ten Berge RL, Oudejans JJ, Dukers DF, Meijer JW, Ossenkoppele GJ, Meijer CJ: Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin’s disease: an independent biological prognostic marker. Leukemia 2001;15:458–464.
  17. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA: Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–1473.
  18. Muenst S, Hoeller S, Dirnhofer S, Tzankov A: Increased PD-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009;40:1715–1722.
  19. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S: Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica 2008;93:193–200.
  20. Van den Berg A, Visser L, Poppema S: High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin’s lymphoma. Am J Pathol 1999;154:1685–1691.
  21. Skinnider BF, Mak TW: The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4297.
  22. Schiffer CA, Levi JA, Wiernik PH: The significance of abnormal circulating cells in patients with Hodgkin’s disease. Br J Haematol 1975;31:177–183.
  23. Ree HJ, Kadin ME: Macrophage-histiocytes in Hodgkin’s disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer 1985;56:333–338.
  24. Coppleson LW, Rappaport H, Strum SB, Rose J: Analysis of the Rye classification of Hodgkin’s disease. The prognostic significance of cellular composition. J Natl Cancer Inst 1973;51:379–390.
  25. Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 2010;362:875–885.
  26. Tzankov A, Zimpfer A, Went P, Maurer R, Pileri SA, Geley S, Dirnhofer S: Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Mod Pathol 2005;18:90–96.
  27. Greil R, Holzner B, Kemmler G, et al: Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin’s disease from 1969 to 1994. Eur J Cancer 1999;35:698–706.
  28. Fong D, Steurer M, Greil R, et al: Hodgkin lymphoma in Tyrol – a population-based study. Ann Hematol 2009;88:449–456.
  29. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S: Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010;51:199–212.
  30. Adams H, Campidelli C, Dirnhofer S, Pileri SA, Tzankov A: Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opin Ther Targets 2009;13:1137–1145.
  31. Enblad G, Molin D, Glimelius I, Fischer M, Nilsson G: The potential role of innate immunity in the pathogenesis of Hodgkin’s lymphoma. Hematol Oncol Clin North Am 2007;21:805–823.
  32. Cao X, Cai SF, Fehniger TA, et al: Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007;27:635–646.